(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit ... due to strong demand for its devices used in hip and knee procedures. Combined sales at Zimmer's hips and ...
Within the Knees business, the company earlier faced some challenges from a supply standpoint, which were expected to be resolved in the latter half of 2024. Meanwhile, Zimmer Biomet is likely to ...
Global Knees grew 5.6% in the quarter with the U.S. growing 3.9% and international growing 8%. Global Hips grew 4%, with the U.S. growing 3.2% and international growing 4.8%. S.E.T. segment grew 8.4%, ...
Empowered Funds LLC lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 15.4% in the 4th quarter, ...
Zimmer Biomet Holdings, Inc., together with its subsidiaries ... and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine ...
Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...
Zimmer Biomet provided 2025 guidance of constant currency ... particularly in hips, knees, and robotics. Adjusted EPS for Q4 2024 came in at $2.31 vs. analysts' estimate of $2.29.
(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year ... due to strong demand for its devices used in hip and knee procedures. Combined sales at Zimmer's hips and knees ...
Knee product sales increased 5.1% to $839.2 million ... and to grow at a much faster pace," said Ivan Tornos, Zimmer Biomet's President and CEO. Operating margin improved to 19.2% from 18.3% ...